EP2621478A2 - Method of preparing a dry powder from a water bacteria extract-concentrate - Google Patents
Method of preparing a dry powder from a water bacteria extract-concentrateInfo
- Publication number
- EP2621478A2 EP2621478A2 EP11829971.8A EP11829971A EP2621478A2 EP 2621478 A2 EP2621478 A2 EP 2621478A2 EP 11829971 A EP11829971 A EP 11829971A EP 2621478 A2 EP2621478 A2 EP 2621478A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- glycine
- alanine
- asparagine
- homogenate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present disclosure generally relates to apparatuses and methods for producing a dry powder from a water bacteria concentration. More particularly, the present disclosure relates to a method of producing a dry powder cancer treatment substance from a cultured bacterial growth in water.
- the model that these professionals use it that of: (1) First determining the cause of the disease, assuming that there is a traditional cause and effect relationship. Namely, that there is present in the environment a direct cause of the cancer or that a genetic abnormality may be an inducing factor in the genesis of the cancer onset. (2) Next the introduction of an outside force into the body to destroy the cause. This is typically accomplished by the administration of chemicals such as those used in current chemotherapy, or by means of gene modification. Finally, (3) the health professionals help the patient's body to overcome the disease. This can be accomplished through further chemical therapy to counteract the side effects of the chemotherapy, through nutrition, or physical therapy. Most typically, a combination of all three is employed to help the patient to recovery. Yet, at the conclusion the cancer is not considered cured, just in remission with periodic monitoring to determine its status over time.
- cancer may not follow the protocol of the above-described model for treating other known diseases, but may require an alternate treatment protocol.
- the characteristics of the cancer must be taken into consideration and the protocol must be optimized to those characteristics.
- the characteristics of cancer are best evaluated in light of human evolution as a cause of cancer. Human evolution is an ongoing process and has never ceased. Cancer is an uncontrolled growth of anaerobic tissue (i.e. tissue that does not need oxygen to live and grow) and that is why killing cancer tissue is so difficult. Most of our pharmaceutically based treatments build on deprivation of oxygen to the diseased tissue or to infecting bacteria with reason to kill it. However, cancer does not require oxygen and thus effectively makes the cancer indestructible. Further, cancer tissue has a barrier that prohibits our immune system from recognizing the cancer as a foreign body and therefore the immune system's ability to kill the cancer.
- Preadaptation Theory postulates that adaptation characteristics already exist as a characteristic of the organism, and that those organism characteristics are merely awaiting certain conditions to surface and manifest themselves in the organism.
- Preadaptation is an anatomical structure, physiological process, or behavior pattern in an organism that is by chance highly suited to a new habitat to which the organism migrates or that improves the chance of organism survival following a change in environmental conditions such as the development of lungs in an organism when moving from an aquatic environment to one of dry land.
- the implication is that all life forms have the prerequisite genetic material necessary to insure survival in future generations when changes in the external environment threaten the organism's existence.
- One such change is the oxygen concentration in the earth's atmosphere.
- the only way to treat this kind of aberration is to signal the tissue that the future has already come in the present. This will stop the aggression of the cancer tissue and allow our immune system to destroy it. Therefore, the means to fight cancer is by introducing a medicine to trick the cancer that time and evolution has progressed to an anaerobic environment and is thus subject to the body's immune system. Therefore, a medicine to signal the cancer tissue that it is in an anaerobic environment and subject to regulation by the body's immune system and a method of producing the medicine is needed.
- the present disclosure is generally directed to a method to produce a dry powder cancer treatment substance from a cultured bacterial growth in water and includes the steps of culturing a desired bacterial growth in a solvent to produce a bacterial mass, which is then homogenized to a homogenate. Solid particulates are then removed from the homogenate by passing the homogenate through a first filter. The filtered homogenate is collected and filtered through a second filter to remove high molecular weight chemicals from the solution. The homogenate is concentrated by separating the solvent from the homogenate yielding an extract to increase the solids content and produce a concentrated homogenate. The concentrated homogenate is dried to evaporate remaining solvent and transform the concentrated homogenate to a powder. The powder is encapsulated in individual capsules, which in turn are packaged in blister packs.
- Another aspect of the disclosure is directed to a method for treating cancer and includes beginning the patient on a specialized diet including two herbal mixtures and at least one cereal meal selected from the grain group consisting of buckwheat, rice, whole grain soft wheat, and millet. After waiting a time period comprising three to five days beginning administration to the patient of an anti-cancer agent intravenously once per day in an amount at least 200 milligrams anti-cancer agent per 200 milliliters of 0.9% saline solution and further wherein the anti-cancer agent includes at least one peptide from the group consisting of H-Glycine-Alanine-OH, H-Glycine-Alanine- Asparagine-OH, H-Glycine-Alanine-Asparagine-Aspartic Acid-OH, H-Glycine- Alanine-Asparagine-Cysteine-OH, H-Glycine- Alanine- Asparagine-Threonine-OH, and H-Glycine-Alanine-Aspara
- FIG. 1 presents a schematic diagram of a system for producing medicinal capsules for a bacteria- water culture
- FIG. 2 presents a flow chart of the steps required to produce medicinal capsules from a bacteria- water culture.
- bio-evolution is a process of transformation of conditions favoring survival, and assured by an increased resistance to an oxygen deficit.
- the role of oxygen in the human body is to accept H+ ions protecting tissue from acidosis. In anaerobic tissue, pyruvate is transformed into lactate, and eliminates total dependency on oxygen.
- Cancer is essentially an uncontrolled growth of anaerobic tissue. With respect to their development, tumors can be classified as three types; (1) slow growth and highly differentiated, (2) intermediate growth and well differentiated, and (3) rapid growth and poorly differentiated. Within this development there is seen an increase of anaerobism and a decrease in the quantity of mitochondria which are responsible for aerobic oxidative phosphorylation. Much work has shown that as a poorly differentiated tumor increases in size, the tumor tends to take on properties of fetal tissue, particularly with respect to its isozyme patterns and its bioenergetics properties.
- HIF-la hypooxia- inducible transcriptional factor
- the cause of the cancer is the result of a future adaptation being experienced in the present. Since the cause of the cancer is related to perceived future environmental conditions, it can't be destroyed, but rather the main characteristics of the abnormality must be examined to determine the perceived future environment that the cancer has prematurely adapted to. A messenger must then be introduced that will telegraph the organism that the future has already arrived and therefore stop hostility against the present condition.
- the preadaptational syndrome presents itself as an "illness” but its etiology is completely different from that of the disease model.
- Cancer can be identified as a preadaptational syndrome by correlating the character of the abnormality with the trend of environmental changes (i.e. decreasing oxygen concentration in the atmosphere).
- An effective anti-cancer drug should thus be a messenger to the cancerous cells telegraphing to the cells that the future conditions to which it has prematurely adapted has already arrived.
- Sarcoma growth in vitro has been successfully arrested using non-hormonal factor received from fetal bone marrow fibroblasts.
- Peptides from microorganisms or fungi that developed in a time when earth was anaerobic or with a very low oxygen level will possess strong anti-cancer activity. Such microorganisms must be cultured in quantity and processed into a form suitable for ingestion by a cancer patient.
- FIG. 1 shows a production system 100 for producing medicinal capsules from a bacteria-water culture possessing the desired anti-cancer characteristics, which is one of the preferred embodiments of the present invention and illustrates its various components.
- System 100 includes a bioreactor 102 in which microorganisms such as bacteria are cultured and grown to a desired mass in anaerobic conditions. Since the biologic fermentation process creates a significant amount of heat, the bioreactor includes a refrigeration system to maintain the bioprocess at a constant temperature optimal for fermentation of the bacteria.
- the solvent or medium, such as water, in which the bacteria are fermented, can also include the necessary nutrients to feed the bacteria.
- Bioreactor can also include an agitator to mix the nutrients and keep the fermentation process homogenous.
- the bacterial mass 103 is transferred to sonicator 104 wherein bacterial mass 103 is subjected to sound energy, usually in the form of ultrasonic sound, to halt the fermentation process.
- the sonic energy further acts to disrupt the individual cell membranes of the bacteria in bacterial mass 103 and thereby release the cellular contents into the solvent.
- the broken down bacterial solution 105 can then be transferred to a homogenizer 106 wherein the cellular contents and the solvent are homogenized into a unified solution 107.
- the homogenized solution 107 is passed through a first filter 108 to remove solid particulates 110 upon which the filtered homogenate 112 is collected in cooling tank 114 where filtered homogenate 112 is cooled to a desired processing temperature.
- the cooled and filtered homogenate 116 is passed through a second filtering system or separator having special size filters where high molecular weight chemicals 120 are removed.
- the resulting filtered homogenate 122 is then stored in a temperature controlled storage 124.
- Stored homogenate 126 is then transferred to a reverse osmosis plant 128 where the solvent 129 is separated from homogenate 126 to produce an extract 130 that is highly concentrated with the cellular contents of the bacterial mass.
- Reverse osmosis plant typically employs four membrane elements with a spiral membrane area of 4 - 56 square meters and a permeated spiral capacity of 20 - 200 gallons per hour at pressures up to 600 psig and temperatures up to 200 degrees Fahrenheit. At least a portion of the permeate 129 from the reverse osmosis process can be recycled to cooling tank 114 to aid in the optimization and efficiency of the process. Reverse osmosis plant 128 can concentrate up to a certain level of concentration, but does not completely remove all solvent. When optimal concentration is reached, the reverse osmosis process is halted and extract 130 is transferred to spray dryer 132 in a continuous drying process.
- Spray dryer 132 receives extract 130 at an atomizer 140 where extract 130 is transformed into small droplets and introduced into drying chamber 134.
- a flow of hot air 136 is also introduced into drying chamber via air inlet 138 to evaporate the solvent such as water whereupon the extract 130 is transformed to a powder 142.
- Powder 142 is further transferred to a first cyclone 144 whereupon the powder undergoes a first separation process from the warm wet air 150 of the drying chamber 134.
- the powder is transferred to powder cooling system 146 where it is subjected to cool dry air.
- the cooled powder 148 is then transferred to a second cyclone to remove additional wet air 150 to achieve a desired relative humidity of less than 2.5%.
- the dried powder 154 is then transferred to dry room 155.
- dry room 155 is maintained at a relative humidity of 2.5%.
- Dry room 155 contains a capsule filling machine 156 where dried powder 154 is dosed and the individual doses are encapsulated into a desire capsule size, which is convenient for administration to a patient to be treated.
- a blister machine 158 which packages a plurality of capsules 157 output from capsule filling machine 156 into known forms of blister packs 160 for distribution to health care professionals engaged in treating cancer patients.
- a flow chart 200 represents a method of producing a dry powder cancer treatment substance from a cultured bacterial growth in water.
- the process begins at step 202 where in step 204 a bacterial growth is cultured or fermented in a solvent such as water to produce a desired bacterial mass. The resulting bacterial mass is then homogenized with the solvent in step 206 to produce a homogenate for further processing.
- the homogenate is passed through a first filter to remove solid particulates from the homogenate.
- the filtered homogenate is collected in step 210 and then subjected to a second filtering process to remove high molecular weight chemicals in step 212.
- step 214 the homogenate is concentrated by separating the at least a portion of the solvent from the homogenate to yield a concentrated extract having increased solids content.
- the concentrated extract is dried by evaporating the remaining solvent in step 216 to produce a powder.
- step 218 the powder is encapsulated in individual capsules, which are then packaged into blister packs in step 220 whereupon the process ends at step 222.
- the encapsulated powder produced from the bacterial mass includes one or more peptides derived from L-amino acids extracted from the above described homogenized bacterial mass.
- the peptides so derived are: H-Glycine-Alanine-OH, H-Glycine- Alanine- Asparagine-OH, H-Glycine- Alanine- Asparagine-Aspartic Acid- OH, H-Glycine- Alanine- Asparagine-Cysteine-OH, H-Glycine- Alanine- Asparagine- Threonine-OH, and H-Glycine- Alanine- Asparagine-Proline-OH.
- a cancer therapy system is designed to attack cancer in two ways, by simultaneously detoxifying the body with a special diet and destroying cancer cells using a drug including the peptides, which has been shown to decrease tumor size and metastases with minimal side effects in animal models.
- the cancer treatment system is designed to eliminate the environment that allows the cancer to thrive while cancer cells are attacked directly with a non-toxic drug.
- the cancer treatment system decreases side-effects from standard cancer therapies like chemotherapy and radiation, and destroy cancer cells with anti-cancer agents.
- the multi-faceted approach of the treatment system ensures the best quality of life possible, by treating the cancer as well as the circumstances that allowed the cancer to thrive.
- the cancer therapy system combines the anti-cancer agent, administered as an IV injection, with a strict diet of two specialized herbal mixtures and four types of cereal meal: buckwheat, rice, whole grain soft wheat, and millet. This system, which is administered for 2-3 weeks, kills cancer cells while detoxifying the body, thereby enhancing its ability to eliminate the myriad of proteins and waste created in the process.
- the cancer therapy system is a one-of-a-kind approach to killing cancer cells while enhancing general health and minimizing side-effects of other cancer therapies, such as chemotherapy and radiation.
- the anti-cancer agent including at least one of the above peptides is a combination of molecular signals derived from special bacteria, which interfere with normal functioning of cancer cells but are harmless to normal cell processes.
- Preliminary results from in vivo studies in mice injected with melanoma shown in Graph 1 and Graph 2 below demonstrate that injections of the anti-cancer agent decreased tumor size and the number of metastases when compared with controls (p ⁇ 0.05), with no toxicity.
- the anti-cancer agent can be combined with any standard cancer therapies to enhance their effectiveness and improve the speed of recovery of cancer patients. Overall, cancer patients benefit from an effective, non-toxic therapy option that is compatible with all other cancer therapies on the market.
- Graph 1 illustrates tumor volume in mice injected with B16 melanoma.
- Groups 1 and 2 represented in the graph by squares and circles, respectively are results obtained from mice injected with melanoma and treated with the anti-cancer agent while Group 3 represents control mice. As shown, by day 21 tumor size in both anti-cancer agent treated groups were significantly small than in the control group (p ⁇ 0.05).
- Graph 2 illustrates a normalized number of metastases in the lungs of mice injected with B16 melanoma.
- Experimental groups 1 and 2 represent results obtained from mice injected with melanoma and treated with the anti-cancer agent, while Group 3 represents control mice. These results show that the number of metastases in the lungs of both anti-cancer agent treated groups were significantly smaller than in the control group (p ⁇ 0.05).
- the cancer therapy system combines the anti-cancer agent with a strict diet specially designed to enhance the anti-cancer agent's effectiveness and improve the patient's quality of life.
- the diet includes creating a steady regimen that combines two unique herbal mixtures with one of four types of cereal meal: buckwheat, rice, whole grain soft wheat, and millet.
- the cereal meal helps to re-establish homeostasis between organ systems by removing potentially harmful materials that have accumulated in the intestines throughout the life of the patient, thereby easing the burden on the immune system that regulates intestinal flora. With time, this decreases the detoxification load on the liver and the amount of pathogenic bacterial flora that the immune system surrounding the intestines has to keep in check.
- the treatment regimen begins with the patient starting the specialized diet.
- Administration of the anti-cancer agent begins 3-5 days after the start of the diet and is administered intravenously once per day (200mg per 200mL 0.9 NaCl saline).
- the anti-cancer agent is administered for 2-3 weeks. Additional supplements and therapies may be considered depending on the status of the patient's disease.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38830410P | 2010-09-30 | 2010-09-30 | |
PCT/US2011/054238 WO2012044939A2 (en) | 2010-09-30 | 2011-09-30 | Method of preparing a dry powder from a water bacteria extract-concentrate |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2621478A2 true EP2621478A2 (en) | 2013-08-07 |
EP2621478A4 EP2621478A4 (en) | 2014-08-13 |
Family
ID=45893766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11829971.8A Withdrawn EP2621478A4 (en) | 2010-09-30 | 2011-09-30 | Method of preparing a dry powder from a water bacteria extract-concentrate |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2621478A4 (en) |
JP (1) | JP2013540125A (en) |
KR (1) | KR20130137637A (en) |
CN (1) | CN103179958A (en) |
AU (1) | AU2011308616A1 (en) |
BR (1) | BR112013007641A2 (en) |
CA (1) | CA2813253A1 (en) |
EA (1) | EA201370083A1 (en) |
IL (1) | IL225505A0 (en) |
WO (1) | WO2012044939A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102227125B1 (en) | 2019-05-15 | 2021-03-11 | 숙명여자대학교산학협력단 | Method for storing bacteria and dry power produces by the same method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060974A2 (en) * | 2000-02-16 | 2001-08-23 | Norferm Da | Method for an extraction of proteins from a single cell |
WO2010065520A1 (en) * | 2008-12-01 | 2010-06-10 | Alexion Pharmaceuticals, Inc. | Methods for preparing aerolysin polypeptides or conjugates thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58874B2 (en) * | 1979-08-30 | 1983-01-08 | 株式会社 目黒研究所 | Glycoprotein WENAC and its production method |
JPS58150595A (en) * | 1982-03-03 | 1983-09-07 | Banyu Pharmaceut Co Ltd | Antitumor antibiotic ail |
JPS61280437A (en) * | 1985-05-29 | 1986-12-11 | Suntory Ltd | Production of novel polypeptide having antitumor activity |
EP0416892B2 (en) * | 1989-09-05 | 1998-10-21 | Ajinomoto Co., Inc. | Agents for the prevention and treatment of diarrhoea |
IL101410A0 (en) * | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Formulation for the treatment of cancer |
US20060233808A1 (en) * | 2003-04-04 | 2006-10-19 | David Deperthes | Peptabody for cancer treatment |
US20070009490A1 (en) * | 2003-10-02 | 2007-01-11 | Conte Anthony E | Dried biotherapeutic composition, uses, and device and methods for administration thereof |
CN101824406B (en) * | 2009-03-06 | 2012-05-30 | 中国医学科学院放射医学研究所 | Recombinant beta-lactamase-RGD-fusion protein and application thereof in medicine |
-
2011
- 2011-09-30 KR KR1020137010763A patent/KR20130137637A/en not_active Application Discontinuation
- 2011-09-30 CN CN2011800512589A patent/CN103179958A/en active Pending
- 2011-09-30 WO PCT/US2011/054238 patent/WO2012044939A2/en active Application Filing
- 2011-09-30 EP EP11829971.8A patent/EP2621478A4/en not_active Withdrawn
- 2011-09-30 CA CA2813253A patent/CA2813253A1/en not_active Abandoned
- 2011-09-30 BR BR112013007641A patent/BR112013007641A2/en not_active IP Right Cessation
- 2011-09-30 AU AU2011308616A patent/AU2011308616A1/en not_active Abandoned
- 2011-09-30 EA EA201370083A patent/EA201370083A1/en unknown
- 2011-09-30 JP JP2013531915A patent/JP2013540125A/en active Pending
-
2013
- 2013-04-02 IL IL225505A patent/IL225505A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060974A2 (en) * | 2000-02-16 | 2001-08-23 | Norferm Da | Method for an extraction of proteins from a single cell |
WO2010065520A1 (en) * | 2008-12-01 | 2010-06-10 | Alexion Pharmaceuticals, Inc. | Methods for preparing aerolysin polypeptides or conjugates thereof |
Non-Patent Citations (1)
Title |
---|
See also references of WO2012044939A2 * |
Also Published As
Publication number | Publication date |
---|---|
KR20130137637A (en) | 2013-12-17 |
WO2012044939A2 (en) | 2012-04-05 |
AU2011308616A1 (en) | 2013-04-18 |
CA2813253A1 (en) | 2012-04-05 |
CN103179958A (en) | 2013-06-26 |
EA201370083A1 (en) | 2014-01-30 |
IL225505A0 (en) | 2013-06-27 |
EP2621478A4 (en) | 2014-08-13 |
JP2013540125A (en) | 2013-10-31 |
BR112013007641A2 (en) | 2019-09-24 |
WO2012044939A3 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1676908B1 (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
CN1748713A (en) | Process for preparing chick embryo element | |
CN105595224A (en) | Sea cucumber dunaliella salina glucosan selenium preparation and preparation process | |
CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
CN103142765A (en) | Total nutrient ganoderma lucidum snake wine containing rich selenium germanium nano elements and vitamins | |
KR20130127525A (en) | Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins | |
EP2621478A2 (en) | Method of preparing a dry powder from a water bacteria extract-concentrate | |
CN106728038A (en) | A kind of Chinese medicine fodder pre-mixing agent for preventing and treating aquatic livestock disease in the liver and gallbladder and preparation method thereof | |
CN106924449A (en) | One kind prevents and treats vibriosis Chinese medicine composition and its preparation method and application | |
CN108714189B (en) | Liver-protecting intestinal microecological regulator based on liver-intestinal axis and preparation method thereof | |
KR101143363B1 (en) | The preparing method of Centella asiatica nanoparticle using chitosan, the product, and the food containing the product | |
CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
CN113662987A (en) | Preparation method of toad feeding liposome for liver cancer | |
CN113234178A (en) | Nostoc sphaeroids kutz oligosaccharide and preparation method and application thereof | |
JP5882635B2 (en) | Maitake-derived polymeric α-glucan | |
CN105878472A (en) | Preparation method and application of intelligent biological-series preparations for guiding cell regeneration to treat cancers | |
CN109294984A (en) | A kind of Lentinan and preparation method thereof of internal efficient amplification NK cell | |
CN1337254A (en) | Cancer-treating Chinese medicine and its prepn | |
JPH06217712A (en) | Feed for crustacean | |
CN1261103C (en) | Microbial drug material, its preparing method and usage | |
KORSAKOV | THE VALUE OF HUMIC ACIDS FOR HUMANS | |
KR20230006634A (en) | Ginger processed product manufacturing method, and ginger processed product | |
CN104738619B (en) | A kind of anti-radiation health care food compositions and preparation method thereof | |
CN112274628A (en) | Combined medicinal powder capable of treating early death of meat ducks and preparation process and use method thereof | |
JPH09309838A (en) | Promotor for biological defense function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130502 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140710 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61J 3/02 20060101ALI20140704BHEP Ipc: A61K 38/06 20060101ALI20140704BHEP Ipc: A61K 38/07 20060101ALI20140704BHEP Ipc: A61K 9/16 20060101ALI20140704BHEP Ipc: A61K 38/05 20060101ALI20140704BHEP Ipc: A61K 9/48 20060101AFI20140704BHEP Ipc: A61J 3/07 20060101ALI20140704BHEP Ipc: A61K 38/01 20060101ALI20140704BHEP Ipc: A61P 35/00 20060101ALI20140704BHEP Ipc: A61K 38/16 20060101ALI20140704BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150210 |